Could restarting chemo after liver surgery keep cancer away?

NCT ID NCT06501482

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people with colorectal cancer that spread to the liver, who had good results from chemotherapy before surgery. After removing the liver tumors, half will restart the same chemo (FOLFIRI) and half will get no further treatment. The goal is to see if the extra chemo improves the chance of staying cancer-free for 3 years. About 254 patients will take part across 30 French hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOLFIRI chemotherapy (irinotecan, leucovorin, and 5-FU)
What this could lead to: If successful, this could show that restarting chemotherapy after liver surgery helps prevent cancer from coming back, offering a new treatment option for these patients.
What could go wrong: This is a Phase 3 trial, but the expected benefit is modest (from 25% to 40% disease-free at 3 years). Chemotherapy has side effects, and not all patients may tolerate it. The results may not apply to those who could take oxaliplatin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER COLORECTAL LIVER METASTASES

Contacts and locations

Locations

Hôpital Kremlin Bicêtre
RECRUITING

Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.